In addition, in the specific case of sexual dysfunction, findings from clinical trials clearly underestimate this problem because of the nonspecific assessment of these adverse effects; the incidence of sexual dysfunction has been shown to increase when specific assessment measures are used (Knegtering, Boks, & Brink, 1998; Monteiro, Noshirvani, Marks, & Lelliott, 1987; Montejo et al., 1996). Therefore, clinical trials are not always applicable to clinical practice (Fleischhacker & Hummer, 1999). More naturalistic studies are therefore required to test the clinical value of these drugs in routine daily clinical practice as well as to ascertain how the drugs are actually used and how the sideeffects are managed by physicians at their offices. This was the purpose of the Estudio de Investigacion de Resultados en Esquizofrenia (Outcomes Research Study in Schizophrenia; EIRE study), conducted in Spain. The results of this study are partially reported in this article. The objectives of this crosssectional study were to assess the frequency of different adverse effects—extrapyramidal, weight changes, and sexual dysfunction and other reproductive side-effects—that occur with the antipsychotics most commonly used in Spain and to evaluate the management of such adverse effects by the clinical psychiatrist. This article addresses sexual dysfunction and other reproductive side-effects.

###

View Full Text Article
###

Authors:

J. BOBES AND M. P. GARCÍA-PORTILLA
Department of Psychiatry, University of Oviedo, Spain

  J. REJAS AND G. HERNÁNDEZ
Outcomes Research Unit & Medical Division, Laboratories Pfizer SA, Madrid, Spain

M. GARCIA-GARCIA, F. RICO-VILLADEMOROS
Brométrica, Barcelona, Spain

A. PORRAS

Journal of Sex & Marital Therapy, 29(2):125–147, 2003
Copyright © 2003 Brunner-Routledge
0092-623X/03 $12.00 + .00
DOI: 10.1080/00926230390155023

This study has been funded by Laboratorios Pfizer SA, Madrid, Spain. Preliminary results were presented at the American Psychiatric Association (APA) Annual Meeting, New Orleans, May 5–10, 2001 and at the International Society for Pharmacoeconomics and Outcomes Research Fourth Annual European Congress (ISPOR), Cannes, France, November 11–13, 2001. The authors have written this article on behalf of the EIRE Study Group, whose member include S. Álvarez (Asturias), P. Álvarez (Valladolid), M. T. Bascarán (Asturias), M. Bernardo (Barcelona), J. A. Blanco (Valladolid), J. Bobes (Asturias), J. Busto (Badajoz), F. Campo (Cádiz), M. S. Casares (Madrid), S. Catarineu (Barcelona), M. Cavero (Barcelona), E. Daniel (Cáceres), C. Deza (Burgos), V. Elvira (Alicante), J. C. Espín (Madrid), Z. Fernández (Sevilla), C. Fernández (Zamora), J. I. Franch (Valladolid), F. Galán (Badajoz), M. T. Gallego (Zamora), G. García (Barcelona), M. García (Baleares), M. A. Garzón (Salamanca), J. Gómez-Trigo (Madrid), M. P. G.-Portilla (Asturias), M. González-Quirós (Asturias), L. Gutiérrez (Orense), M. Hemmings (Zamora), O. Herreros (Santa Cruz de Tenerife), C. Iglesias (Asturias), J. J. López (Granada), E. Martín (Madrid), M. Martín (Navarra), F. Martín (Burgos), J. M. Martínez (Zamora), M. J. Martínez (Zamora), J. Matías (Salamanca), J. Medina (Madrid), M. Á. Medina (Burgos), P. Megía (Palencia), M. J. Merino (Asturias), A. Monforte (Zamora), J. Mons (Burgos), A. L. Montejo (Salamanca), J. M. Montes (Madrid), M. A. More (Madrid), A. Muñoz (Madrid), F. Orengo (Madrid), A. Pérez (Pontevedra), J. L. Pérez-Iñigo (Madrid), J. I. Portilla (Asturias), I. Rubio (Madrid), V. Rubio (Zaragoza), F. Ruíz (Palencia), O. Sanz (Burgos), M. Silvestre (Badajoz), J. A. Solana (Salamanca), A. Soto (Valladolid), J. R. Valle (Sevilla), A. Varona (Burgos), F. Vicente (Madrid).